Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.74 |
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | HPGD | P15428 | 7/20 | 0.74 |
| ▸ | CASP1 | P29466 | 6/20 | 0.74 |
| ▸ | CASP7 | P55210 | 6/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.74 |
| ▸ | TP53 | P04637 | 5/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.71 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.71 |
| ▸ | RECQL | P46063 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25809583 | 0.90 | MEN1 (0.78) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL10037940 | 0.90 | MEN1 (0.78) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL13056258 | 0.89 | ALDH1A1 (0.71) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL13248718 | 0.86 | MEN1 (0.83) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Resokaempferol SCHEMBL30873045 | 0.85 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Resokaempferol SCHEMBL344710 | 0.85 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL19213535 | 0.85 | MEN1 (0.82) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL25209431 | 0.84 | MAPT (0.57) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL7457890 | 0.84 | TP53 (0.72) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL29394036 | 0.83 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7947733-B2 | Phosphorylated pyrone analogs and methods | LIMERICK BIOPHARMA (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110028437-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100189653-A1 | Pyrone analogs for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100144612-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090082400-A1 | SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS | LIMERICK BIOPHARMA, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | MEN1 4072/4885KMT2A 3401/4885CYP3A4 708/4885 |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | MEN1 535/4885KMT2A 4673/4885CYP3A4 718/4885 |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | SLC2A1, SLC2A2, SLC2A3 | MEN1 4409/4885KMT2A 4599/4885CYP3A4 3140/4885 |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | PC, PCK1, PYGL | MEN1 2302/4885KMT2A 4512/4885CYP3A4 2300/4885 |
| US-20100189653-A1 | Pyrone analogs for therapeutic treatment | PC, GLS2, CYP27A1 | MEN1 1731/4885KMT2A 4385/4885CYP3A4 718/4885 |
| US-20110028437-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | MEN1 4072/4885KMT2A 3401/4885CYP3A4 708/4885 |
| US-20100144612-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | MEN1 4072/4885KMT2A 3401/4885CYP3A4 708/4885 |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | MEN1 4072/4885KMT2A 3401/4885CYP3A4 708/4885 |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | MEN1 535/4885KMT2A 4673/4885CYP3A4 718/4885 |
| US-20090082400-A1 | SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS | PGF, ABCG2, PYGB | MEN1 3857/4885KMT2A 4497/4885CYP3A4 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.